Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2013 Jun;60(6):1022-6. doi: 10.1002/pbc.24427. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.

Author information

1
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. amar.gajjar@stjude.org

Abstract

In the US, approximately 2,500 children are diagnosed annually with brain tumors. Their survival ranges from >90% to <10%. For children with medulloblastoma, the most common malignant brain tumor, 5-year survival ranges from >80% (standard-risk) to 60% (high-risk). For those with high-grade gliomas (HGGs) including diffuse intrinsic pontine gliomas, 5-year survival remains <10%. Sixty-five percent patients with ependymoma are cured after surgery and radiation therapy depending on the degree of resection and histopathology of the tumor. Phase II trials for brain tumors will investigate agents that act on cMET, PDGFRA, or EZH2 in HGG, DIPG, or medulloblastoma, respectively. Phase III trials will explore risk-based therapy stratification guided by molecular and clinical traits of children with medulloblastoma or ependymoma.

PMID:
23255213
PMCID:
PMC4184243
DOI:
10.1002/pbc.24427
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center